Niagen Bioscience names Martin Hendrix strategic adviser for corporate strategy, M&A

• Niagen Bioscience’s NAD Pharmaceuticals unit engaged Red Sky Partners as strategic adviser to advance NB4168, a small-molecule investigational drug candidate.
• Red Sky advisers include Pauline Jen Ryan, a longtime biotech operator and former SVP of corporate development and operations at ImmunoGen.
• Red Sky also includes Christopher Kiritsy, a former Kos Pharmaceuticals executive involved in building the Niaspan franchise; later co-founded Arisaph Pharmaceuticals.
• Separately, Niagen brought in Martin Hendrix, a former Nestlé Health Science M&A lead, as strategic adviser on corporate strategy, business development, potential M&A.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260917959565) on September 17, 2026, and is solely responsible for the information contained therein.